提供者:上海雅吉生物科技有限公司 发布时间:2026/9/29 11:38:37 阅读次数:104次 进入该公司店铺
文章标题:Paris saponin VII suppresses osteosarcoma progression by targeting VEGFR2 and PD-L1 to enhance anti-angiogenic and immunotherapeutic efficacy
作者列表:Ma Zuyi, Sun Jia, Wu Xin, Shang Changzhen, Li Binglu
影响因子:6
期刊:Cancer Cell International
发表时间:2026-4-6
DOI:10.1186/s12935-026-04289-0
文献主题:Abstract
Objective
To investigate the inhibitory effects and underlying mechanisms of Paris saponin VII (PS VII) on osteosarcoma (OS) progression.
Methods
Human osteosarcoma MG63 cells were treated with PS VII at concentrations of 0, 1, and 10 µmol·L⁻¹. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay, and clonogenic capacity was evaluated by colony formation assays. Potential molecular targets of PS VII were predicted using the SwissTargetPrediction database. Intersection targets between PS VII-related targets and OS differentially expressed genes (DEGs) were identified, followed by protein–protein interaction (PPI) network construction to screen core targets. Molecular docking was performed to validate compound–target interactions. Western blotting was used to verify the regulatory effects of PS VII on key protein targets. In vivo, a K7M2 murine osteosarcoma subcutaneous xenograft model was established to evaluate tumor growth and therapeutic synergy with bevacizumab or anti-PD-1 antibody.
① 凡本网注明"来源:阿仪网"的所有作品,版权均属于阿仪网,未经本网授权不得转载、摘编或利 用其它方式使用。已获本网授 权的作品,应在授权范围内使用,并注明"来源:阿仪网"。违者本网将追究相关法律责任。
② 本信息由注册会员:上海雅吉生物科技有限公司发布并且负责版权等法律责任。
版权声明